Phillip Febbo

Phillip Febbo

Chief Scientific Officer and Chief Medical OfficeratVeracyte· In proxies 2023–2025

Pay in FY2025-10% from the year before · Veracyte stock +6.3% the same year

Phillip Febbo was paid $2.5M in FY2025 (Dec), down 10%. Veracyte stock rose 6.3% that year.

Pay$100 in the stock at the end of FY22 → $177
Pay is from the Summary Compensation Table of each Veracyte proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. VeracytePublic company · 3 yr
    • Chief Scientific Officer and Chief Medical Officer2023 – Present · 3 yrStock in role +111%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?